Ignite Creation Date:
2024-05-06 @ 3:42 AM
Last Modification Date:
2024-10-26 @ 11:37 AM
Study NCT ID:
NCT02352948
Status:
COMPLETED
Last Update Posted:
2023-10-11
First Post:
2015-01-28
Brief Title:
A Global Study to Assess the Effects of MEDI4736 Durvalumab Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-01-13
Start Date Type:
ACTUAL
Primary Completion Date:
2018-02-09
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-08-30
Completion Date Type:
ACTUAL
First Submit Date:
2015-01-28
First Submit QC Date:
January 28 2015
Study First Post Date:
2015-02-02
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2019-04-16
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-07-25
Last Update Post Date:
2023-10-11
Last Update Post Date Type:
ACTUAL